注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Acumen Pharmaceuticals Inc是一家臨床階段的生物製藥公司。該公司致力於開發一種針對阿爾茨海默病(AD)根本原因的疾病改善方法。該公司專注於推進靶向免疫治療候選藥物ACU193,並在早期AD患者中建立機制證據。該公司的ACU193是一種人源化單克隆抗體,選擇性靶向抗澱粉樣蛋白β肽低聚物(AbOs),在體外試驗中顯示出功能和保護作用,並在包括轉基因在內的多種動物物種中顯示出體內安全性和藥理活性AD的模型。該公司的治療方法側重於靶向AbOs,這是一種相對於抗體單體和澱粉樣蛋白斑塊的毒性和致病性抗體形式。它正在開髮用於靜脈注射(IV)的ACU193,每4週給藥一次,用於治療早期AD,目前處於I期臨床試驗階段。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Sean Stalfort | 52 | 2018 | Independent Chairman of the Board |
Jeffrey L. C. Ives | 71 | 2014 | Independent Director |
Kimberlee Cobleigh Drapkin | 54 | 2022 | Independent Director |
Laura Stoppel | 36 | 2020 | Independent Director |
Nathan B. Fountain | 60 | 2021 | Independent Director |
Jeffrey L. Cummings | 73 | - | Member of Clinical & Scientific Advisory Board |
Reisa Sperling | - | - | Member of Clinical & Scientific Advisory Board |
Stephen Salloway | - | - | Member of Clinical & Scientific Advisory Board |
Cynthia A. Lemere | - | - | Member of Clinical & Scientific Advisory Board |
Colin Louis Masters | 76 | - | Member of Clinical & Scientific Advisory Board |
Derrell D. Porter | 52 | 2023 | Independent Director |
Lennart Mucke | - | 2022 | Member of the Scientific Advisory Board |
Michael A. Weiner | 76 | - | Member of Clinical & Scientific Advisory Board |
Steven T. DeKosky | - | - | Member of Clinical & Scientific Advisory Board |
Daniel J. O'Connell | 53 | 2006 | CEO & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核